ABSTRACT
Description: Xigris consists of a recombinant human activated protein C, an antithrombotic molecule very similar to the natural human molecule that regulates coagulation. Xigris is produced in a modified human cell line using recombinant DNA technology. It is a 55-kDa glycosylated serine protease consisting of two polypeptide chains (a light and a heavy chain) linked by a disulphide bond. Nine glutamic acid residues present on the light chain are γ-carboxylated and one aspartic acid residue is β-hydroxylated. Xigris is supplied as a lyophilized form (5 mg/vial or 20 mg/vial) to be resuspended before intravenous infusion.
